Brokerages predict that LeMaitre Vascular Inc (NASDAQ:LMAT) will report earnings of $0.18 per share for the current quarter, Zacks reports. Three analysts have made estimates for LeMaitre Vascular’s earnings. The lowest EPS estimate is $0.18 and the highest is $0.19. LeMaitre Vascular reported earnings per share of $0.21 during the same quarter last year, which suggests a negative year over year growth rate of 14.3%. The company is expected to issue its next earnings report on Wednesday, February 20th.

On average, analysts expect that LeMaitre Vascular will report full-year earnings of $1.02 per share for the current financial year. For the next fiscal year, analysts forecast that the firm will report earnings of $0.94 per share, with EPS estimates ranging from $0.88 to $0.99. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.21. LeMaitre Vascular had a net margin of 20.52% and a return on equity of 18.07%. The business had revenue of $24.17 million for the quarter, compared to analyst estimates of $26.06 million.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Thursday. BidaskClub raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, November 23rd. ValuEngine lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research report on Thursday, November 1st. Barrington Research raised shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 target price on the stock in a research report on Monday, October 8th. Finally, Roth Capital raised shares of LeMaitre Vascular from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $39.00 to $34.00 in a research report on Monday, October 8th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. LeMaitre Vascular currently has an average rating of “Hold” and a consensus target price of $35.86.

LMAT stock traded down $0.59 on Thursday, reaching $26.01. 183,100 shares of the company were exchanged, compared to its average volume of 146,816. LeMaitre Vascular has a 12 month low of $25.63 and a 12 month high of $41.28. The firm has a market capitalization of $520.88 million, a P/E ratio of 30.70, a price-to-earnings-growth ratio of 2.17 and a beta of 1.00.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 6th. Investors of record on Tuesday, November 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.

In other LeMaitre Vascular news, Director Michael H. Thomas sold 20,000 shares of the business’s stock in a transaction on Tuesday, October 30th. The shares were sold at an average price of $27.93, for a total value of $558,600.00. Following the sale, the director now owns 20,000 shares of the company’s stock, valued at approximately $558,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 20.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Bessemer Group Inc. increased its holdings in LeMaitre Vascular by 9.4% in the 3rd quarter. Bessemer Group Inc. now owns 21,000 shares of the medical instruments supplier’s stock valued at $814,000 after buying an additional 1,800 shares during the period. Polen Capital Management LLC increased its holdings in LeMaitre Vascular by 24.5% in the 2nd quarter. Polen Capital Management LLC now owns 9,849 shares of the medical instruments supplier’s stock valued at $330,000 after buying an additional 1,941 shares during the period. Strs Ohio increased its holdings in LeMaitre Vascular by 9.5% in the 2nd quarter. Strs Ohio now owns 23,000 shares of the medical instruments supplier’s stock valued at $770,000 after buying an additional 2,000 shares during the period. Rhumbline Advisers increased its holdings in LeMaitre Vascular by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 60,205 shares of the medical instruments supplier’s stock valued at $2,016,000 after buying an additional 2,015 shares during the period. Finally, Legal & General Group Plc increased its holdings in LeMaitre Vascular by 7.1% in the 2nd quarter. Legal & General Group Plc now owns 30,425 shares of the medical instruments supplier’s stock valued at $1,021,000 after buying an additional 2,018 shares during the period. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Read More: Why do companies engage in swaps?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.